A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Neoadjuvant Carboplatin and Paclitaxel, With or Without Debio 1143 in Patients With Newly Diagnosed Advanced Epithelial Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2018
At a glance
- Drugs AT 406 (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary) ; Antineoplastics
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Debiopharm
- 25 Jan 2018 This trial has been discontinued in France.
- 15 Dec 2017 This trial has been discontinued in Spain.
- 07 Dec 2017 This trial has been completed in Belgium (end date: 2017-11-03)